Safety of hypericum in patients with depression: A comparison with conventional antidepressants

CNS Drugs

Volumn 11, Issue 2, 1999, Pages 125-132

  Stevinson, Clare ^a   Ernst, Edzard ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOSULEPIN; FLUOXETINE; HYPERICUM EXTRACT; MIRTAZAPINE; MOCLOBEMIDE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; MENTAL DISEASE; META ANALYSIS; NEUROLOGIC DISEASE; PHOTOPHOBIA; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEROTONIN SYNDROME; SKIN MANIFESTATION; VISUAL DISORDER;

EID: 0032964314     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911020-00004     Document Type: Review

References (35)

1. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253-8
2. Ernst E, St John's wort, an antidepressant? A systematic, criteria-based review. Phytomed 1995; 2 (1): 67-71
3. Department of Health. Prescription Cost Analysis England 1996. Wetherby: Crown, 1997
4. Lancaster S, Gonzalez J. Dothiepin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1989; 38 (1): 123-47
5. Stokes P, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19 (5): 1135-250
6. Fitton A, Faulds D, Goa K. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43 (4): 561-96
7. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997; 96 Suppl. 391: 31-7
8. Theide HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: S54-S56
9. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol 1994; 7 Suppl. 1: S57-9
10. Muller WE, Rolli M, Schafer C, et al. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30 Suppl. 2: 102-7
11. Müller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 31 Suppl.: 16-21
12. Bhattacharya SK, Chakrabarti A, Chatterjee SS. Activity profiles of two hyperforin-containing hypericum extracts in behavioural models. Pharmacopsychiatry 1998; 31 Suppl.: 22-9
13. Montgomery S. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 37-45
14. Donovan S, Dearden L, Richardson L. The tolerability of dothiepin: a review of clinical studies between 1963 and 1990 in over 13,000 depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 1143-62
15. Pande A, Sayler M. Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 1993; 8: 267-9
16. Hilton S, Jaber B, Ruch R. Moclobemide safety: monitoring a newly developed product in the 1990s. J Clin Psychopharmacol 1995; 15 (4) Suppl. 2: 76-83
17. Ernst E, Rand J, Barnes J, et al. Adverse effects, profile of the herbal antidepressant St John's Wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54: 589-94
18. Fulton B, Benfield P. Moclobemide: an update of its pharmacological properties and therapeutic use. Drugs 1996; 52 (3): 450-74
19. Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face to face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496-500
20. Woelk H, Burkard G, Grünwald J. Benefits and risks of the hypericum extract LI 160. Drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 1994; 7 Suppl. I: S34-8
21. Albrecht M, Hubner WD, Podzuweit H, et al. St John's Wort extract in the treatment of depression: observations on the use of Jarsin capsules. Der Kassenarzi 1994; 41: 45-54
22. Grube B, Schermuck S, Hopfenmuller W, et al. Use of a hypericum extract in mild, transient depressive disorders. Eur J Clin Res 1997; 9: 293-302
23. Meier B, Liske E, Rosinus V. Wirksamkeit und Verträglichkeit eines standardisierten Johanniskraut-Vollextrakts (2e117) bei Patienten mit depressiver Symptomatik unterschiedlicher Schweregrade - eine Anwendebeobachlung. Forsch Komplementärmed 1997; 4: 87-93
24. Bombardelli E, Morazzoni P. Hypericum perforatum. Fitoterapia 1995; 66: 43-68
25. Newall CA, Anderson LA, Phillipson JD. Herbal Medicines. London: The Pharmaceutical Press, 1996
26. Golsch S, Vocks E, Rakoski J, et al. Reversible Erhöhung der Photosensitivität im UV-B-Bereich durch Johanniskrautextrakt-Präparate. Hautarzt 1997; 48: 249-52
27. Schulz V, Hansel R, Tyler V. Rational phytotherapy - a physicians' guide to herbal medicine. New York: Springer-Verlag, 1998
28. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St John's wort. Lancet 1998; 352: 1121-2
29. Baillie N. Hypericum - four photosensitivity reactions: Mod Phytotherapist 1997; 3 (2): 24-6
30. Swinkels J, De Jonghe F. Safety of antidepressants, Int Clin Psychopharmacol 1995; 9 Suppl. 4: 19-25
31. Henry J, Alexander C, Sener E. Relative mortality from over-dose of antidepressants. BMJ 1905; 310: 221-4
32. Schmidt U, Harrer G, Kuhn U, el al. Wechselwirkungen von Hypericum-Extract mit Alkohol. Nervenheilkunde 1993; 6: 314-9
33. Tollefson G. Adverse drug reactions/interactions in maintenance therapy. J Clin Psychiatry 1993; 54 Suppl. 8: 48-58
34. Cohen L. Rational drug use in the treatment of depression. Pharmacotherapy 1997: 17 (1): 45-61
35. British National Formulary. London: British Medical Association & The Pharmaceutical Press, 1997; 34: 180